In-Vitro, Protein, RNA and Trials - Clinical Research Informer

RNA interference method could treat muscular dystrophy

Drug Discovery World

DECEMBER 13, 2022

Japanese researchers propose using RNA interference for correcting a mistake in the genetic code of patients with Fukuyama muscular dystrophy. . The genetic anomaly blocks the chemical glycosylation of a biologically important protein. Modifying RNA function. Our initial experiments are therefore of paramount significance.” .

RNA

RNA Genetics Gene In-Vitro

Conversations from ESMO Targeted Anticancer Therapies Congress 2024

Drug Discovery World

MARCH 26, 2024

Additional approaches, such as profiling of RNA and proteins, and the use of artificial intelligence (AI), could be key to providing a more comprehensive picture of a patient’s tumour and enable the use of optimised treatments. MT: Why was STORM attending the conference? MT: What data did you present at the conference?

RNA

RNA In-Vivo In-Vitro DNA

The Utility of Liquid Biopsy in Oncology Clinical Trials

XTalks

NOVEMBER 7, 2022

Gleich, MD, FACS, Senior Vice President, Medical Department, and Dr. Christopher Huth, PhD, Senior Clinical Trial Manager, Clinical Trial Management. Liquid Biopsy Use in Oncology Clinical Trials. These tumor-derived entities are used to derive genomic and proteomic data. Concentration of CTCs in Cancer Patients.

Clinical Trials

Clinical Trials Clinical Trials Trials FDA Approval

FDA-approved drug sensitises brain cancer cells to radiotherapy

Drug Discovery World

JANUARY 23, 2023

This action sensitised GBM cells to radiotherapy both in vitro and in vivo (in mouse models). “Our research has revealed cladribine as a radiosensitiser for GBM treatment by drug repurposing, which can offer multiple advantages,” says Prof Youn. “As GBM is a WHO grade IV brain tumour with dismal prognosis.

FDA Approval

FDA Approval Drugs In-Vivo In-Vitro

Personalized Blood Test Detecting ctDNA Can Help Predict Lung Cancer Relapse

XTalks

APRIL 6, 2022

XTALKS WEBINAR: Using CRISPR interference (CRISPRi) Viability Screens to Map Long Noncoding RNA Dependencies in Tumor Cells. Register for this webinar to get an overview of the role of long non-protein coding RNAs (lncRNAs) in gene regulations. Photo source: Inivata.

DNA

DNA In-Vitro Doctors Doctor

The trends driving ELRIG Drug Discovery 2022

Drug Discovery World

OCTOBER 4, 2022

The pandemic might have affected the number of clinical trials taking place for cell and gene therapies, with activity decreasing by around 15% compared to 2020, but major therapies such as Novartis’ gene therapy drug for spinal muscular atrophy (SMA) Zolgensma still made it to market. . billion, compared to $19.9

Gene Therapy

Gene Therapy Drugs Gene Manufacturing

Roche to launch SARS-CoV-2 Rapid Antigen Test in countries accepting CE mark, allowing fast triage decisions at point of care

The Pharma Data

SEPTEMBER 1, 2020

Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions. Antigen test accurately screens individuals with known exposure to infected SARS-CoV-2 patients, providing fast answers regarding their infection status. Food and Drug Administration (FDA).

In-Vitro

In-Vitro Antibody Medicine Clinical Trials

Statement from Pfizer Chairman and CEO Albert Bourla on Testing Positive for COVID-19

Pfizer

AUGUST 15, 2022

Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. FDA Emergency Use Authorization Statement.

Drugs

Drugs Vaccination Vaccine In-Vitro

Receptor Occupancy Assays by Flow Cytometry: Benefits for Clinical Trials

XTalks

APRIL 22, 2022

Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. In a recent webinar, Dr. Olsson described the benefits of flow cytometric receptor occupancy assays in clinical trials. What is Flow Cytometry?

Clinical Trials

Clinical Trials Clinical Trials Trials Antibody

Lab to jab in 100 days: manufacturing flexibility for future rapid responses

Pharmaceutical Technology

NOVEMBER 22, 2022

Messenger RNA vaccines contain nucleic acids that code for a specific protein, or target antigen, related to a virus or disease. When an mRNA vaccine is administered, a patient’s body produces that protein to prompt a desired immune response. Before COVID-19, Merck held the record for the fastest modern vaccine ever developed.

Manufacturing

Manufacturing Vaccination Vaccine RNA

Pfizer Receives Positive CHMP Opinion for Conversion of PAXLOVID™ Conditional Marketing Authorization to Full Marketing Authorization in the European Union

Pfizer

JANUARY 27, 2023

Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus.

Marketing

Marketing Production Drugs Licensing

Angelman Syndrome Market: Insights Into The Recent Late-Stage Drug Failures And Novel Approaches To Treating This Rare Neurogenetic Disorder

Delveinsight

JANUARY 18, 2021

However, DelveInsight’s Angelman syndrome market analysis report estimates that several approaches focused primarily on the Gene Therapies, Topoisomerase Inhibitors, Cannabidiol, Protein Phosphatase 2A inhibitor, among others are under development to find a cure for the Angelman syndrome. GeneTx and Ultragenyx are co-developing the therapy.

Marketing

Marketing Gene Drugs Protein

Can liquid biopsies transform precision medicine?

Drug Discovery World

JANUARY 17, 2024

Brett Swansiger, Chief Commercial Officer at ANGLE discusses the importance of liquid biopsies in precision medicine trials for cancer. Furthermore, oncology clinical trials are frequently challenged by low enrolment rates, failure to achieve primary endpoints, study design complexity and limited funding 5.

Medicine

Medicine DNA Genome Genomics

Pfizer to Provide U.S. Government with an Additional 3.7 Million Treatment Courses of PAXLOVID™ to Help Combat COVID-19

Pfizer

DECEMBER 13, 2022

Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. The additional 3.7

Drugs

Drugs Licensing Licensing Production

U.S. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™

Pfizer

DECEMBER 20, 2022

Results from these analyses are consistent with previously disclosed efficacy and safety data for the trials. Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™. In the U.S., approximately 7.6

Drugs

Drugs Licensing Licensing Containment

Preparing for new-era drug modalities with technology

Drug Discovery World

OCTOBER 13, 2022

Prior to the pandemic, messenger RNA (mRNA) drug development was niche and predominantly pointed at different disease targets, including infectious diseases and cancers. One aspect that makes mRNA technology popular with drug developers is that its proteins can be easily edited. Why mRNA has potential . The rise of global demand .

Drugs

Drugs Manufacturing Vaccination Vaccine

The use of base editing in stem-cell based therapies

Drug Discovery World

JANUARY 23, 2023

Several clinical trials are underway to evaluate the therapeutic potential of iPSCs across a wide range of applications 3 prompting a global shift towards the uptake of iPSCs as a therapeutic option. Pioneering work in the mid-2000s, led by the Yamanaka group at Kyoto University, further advanced the field of PSCs.

Gene Editing

Gene Editing Gene Engineer DNA

Pfizer Signs Agreement to Provide the European Union with PAXLOVID™

Pfizer

NOVEMBER 23, 2022

Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. This agreement will supply participating countries up to 3.4

Licensing

Licensing Licensing Drugs Manufacturing

Advances in neuroscience drug discovery

Drug Discovery World

FEBRUARY 22, 2024

According to Medicine Discovery Catapult, these include: “Navigating the complexity of the CNS; understanding the disease pathology, and accessing predictable in vitro and in vivo cell models 2 ”. For example, it can take up to it three years to recruit enough participants for a dementia clinical trial. million deaths worldwide” 1.

Drugs

Drugs Gene Clinical Trials Clinical Trials

COVID-19 Pandemic Coverage

XTalks

SEPTEMBER 14, 2020

By the end of August, the World Health Organization (WHO) counted 33 vaccine candidates in some stage of clinical trial evaluation. The company’s candidate vaccine, mRNA-1273, is a synthetic messenger RNA that encodes the stabilized SARS-CoV-2 spike protein. The price of that prize is incalculable. Moderna’s COVID-19 Vaccine.

Vaccination

Vaccination Vaccine Antibody Life Science

Clinical Research Informer

RNA interference method could treat muscular dystrophy

Conversations from ESMO Targeted Anticancer Therapies Congress 2024

Trending Sources

The Utility of Liquid Biopsy in Oncology Clinical Trials

FDA-approved drug sensitises brain cancer cells to radiotherapy

Personalized Blood Test Detecting ctDNA Can Help Predict Lung Cancer Relapse

The trends driving ELRIG Drug Discovery 2022

Roche to launch SARS-CoV-2 Rapid Antigen Test in countries accepting CE mark, allowing fast triage decisions at point of care

Statement from Pfizer Chairman and CEO Albert Bourla on Testing Positive for COVID-19

Receptor Occupancy Assays by Flow Cytometry: Benefits for Clinical Trials

Lab to jab in 100 days: manufacturing flexibility for future rapid responses

Pfizer Receives Positive CHMP Opinion for Conversion of PAXLOVID™ Conditional Marketing Authorization to Full Marketing Authorization in the European Union

Angelman Syndrome Market: Insights Into The Recent Late-Stage Drug Failures And Novel Approaches To Treating This Rare Neurogenetic Disorder

Can liquid biopsies transform precision medicine?

Pfizer to Provide U.S. Government with an Additional 3.7 Million Treatment Courses of PAXLOVID™ to Help Combat COVID-19

U.S. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™

Preparing for new-era drug modalities with technology

The use of base editing in stem-cell based therapies

Pfizer Signs Agreement to Provide the European Union with PAXLOVID™

Advances in neuroscience drug discovery

COVID-19 Pandemic Coverage

Stay Connected